Gamida Cell
Agent46 out of 100, Above median. Agent Readiness. Open the scores section.Agent Readiness: 46/100. Above median. Measured by StartupHub.ai. Median 41.Trust75 out of 100, Above median. Data Trust. Open the scores section.Data Trust: 75/100. Above median. Measured by StartupHub.ai. Median 61.Biotechnology company developing potentially curative cell therapies for cancer patients.
About
Gamida Cell is a clinical-stage biopharmaceutical company focused on developing potentially curative cell therapies for patients with hematologic malignancies and solid tumors. Their proprietary NAM technology expands the number of cells while maintaining their intrinsic properties, aiming to create more effective and accessible cell therapies.
Listed competitors
Also in this space
Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.
Shares Life Sciences, Biotech
AI-powered patient-centric drug simulations to accelerate and de-risk drug development.
Shares Life Sciences, Clinical Trials
AI-powered blood test for early cancer detection and subtyping.
Shares Life Sciences, Biotech
Omnix Medical is developing a novel platform for advanced wound care management.
Shares Life Sciences, HealthTech
Biopharmaceutical company developing innovative punctal plug technology for eye disease therapies.
Shares Life Sciences, Biotech
Biotech company developing next-generation immunotherapy agents to unlock the immune system.
Shares Life Sciences, Biotech
Key facts
- Website
- gamida-cell.com
- Headquarters
- Boston, United States
- Founded
- 1998
- Total funding
- $297M (Post-IPO)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Post-money | Lead investors |
|---|---|---|---|---|
| 27 Mar 2024 | Post-IPO | $30M | Highbridge Capital | |
| 21 Apr 2023 | Post-IPO | $23M | ||
| 16 Feb 2021 | Post-IPO | $75M | $75M | Highbridge Capital |
| 1 Jul 2019 | Post-IPO | $35M | ||
| 19 Jun 2017 | Series G | $40M | $160M | Shavit Capital |
| 15 Oct 2015 | Series F | $5M | $200M | Novartis Venture Fund |
| 19 Aug 2014 | Series F | $35M | $233M | Novartis Venture Fund |
| 15 May 2012 | Series E | $10M | ||
| 20 Jan 2006 | Series D | $16M | Israel Healthcare Ventures | |
| 12 Mar 2003 | Series C | $3M | Teva | |
| 30 Sept 2001 | Series B | $16M | $36M | |
| 20 Feb 2000 | Series A | $7M | $14M | Elscint BioMedical |
Tech stack
Detected on gamida-cell.com, last scanned 31 Oct 2026. Run your own scan
- Frontend
- jQuery, Bootstrap
- Analytics
- Google Analytics 4
- CMS / Builders
- WordPress
- Hosting
- Google Cloud
- Email provider
- Mimecast
- Cookie consent
- Termly
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is Gamida Cell trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Gamida Cell is 75 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Gamida Cell raised?
Gamida Cell has raised a total of $297M in funding. The most recent round on record is Post-IPO.
SEC filings, insider activity, nonprofit links and pay benchmarks for Gamida Cell:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
